SEARCH

Current Edition

Bluebird

FDA clears Rocket to resume testing gene therapy for a rare heart disease

Rocket’s program has been in limbo since early May, when the company surprised investors and analysts with news of the trial’s stoppage. That announcement stalled …

Continue Reading →